ImmuCell Corp Enters Material Definitive Agreement
Ticker: ICCC · Form: 8-K · Filed: Aug 25, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10, $1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
ImmuCell Corp just signed a big deal, watch for financial changes.
AI Summary
On August 20, 2025, ImmuCell Corporation entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is involved in the business of in vitro & in vivo diagnostic substances.
Why It Matters
This filing signals a significant new agreement for ImmuCell Corporation, potentially impacting its financial obligations and future business operations.
Risk Assessment
Risk Level: medium — Entering into new material definitive agreements and financial obligations can introduce new risks and uncertainties for a company.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- 207-878-2770 (phone_number) — Registrant's telephone number
- 56 Evergreen Drive, Portland, Maine 04103 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by ImmuCell Corporation?
The filing states that ImmuCell Corporation entered into a material definitive agreement on August 20, 2025, but does not specify the details of the agreement itself.
What type of financial obligation has ImmuCell Corporation created?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specific details about the obligation.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 20, 2025.
What is ImmuCell Corporation's principal executive office address?
ImmuCell Corporation's principal executive office is located at 56 Evergreen Drive, Portland, Maine 04103.
What is ImmuCell Corporation's business classification according to the SIC code?
ImmuCell Corporation is classified under Standard Industrial Classification code 2835, which pertains to In Vitro & In Vivo Diagnostic Substances.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-08-25 08:00:35
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
- $1 million — k (MCB) pursuant to which the Company's $1 million line of credit with MCB was extended th
Filing Documents
- ea0254361-8k_immucell.htm (8-K) — 27KB
- ea025436101ex10-1_immucell.htm (EX-10.1) — 6KB
- ex10-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-080110.txt ( ) — 201KB
- iccc-20250820.xsd (EX-101.SCH) — 3KB
- iccc-20250820_lab.xml (EX-101.LAB) — 33KB
- iccc-20250820_pre.xml (EX-101.PRE) — 22KB
- ea0254361-8k_immucell_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On August 20, 2025, ImmuCell Corporation (the "Company") entered into an Allonge to and Amendment of Line of Credit (the "Allonge") between the Company and Maine Community Bank (MCB) pursuant to which the Company's $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.
03 Creation of a Direct Financial Obligation or an Obligation
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.
01. Exhibits
Item 9.01. Exhibits. (d) Exhibits . 10.1 Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: August 25, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Executive Officer Date: August 25, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exhibit Index Exhibit No. Description 10.1 Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3